<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01796587</url>
  </required_header>
  <id_info>
    <org_study_id>LOF-0017</org_study_id>
    <nct_id>NCT01796587</nct_id>
  </id_info>
  <brief_title>Non-Interventional Study Among Users Of LoFric Origo</brief_title>
  <official_title>Non-Interventional Study Among Users Of LoFric Origo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wellspect HealthCare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wellspect HealthCare</source>
  <brief_summary>
    <textblock>
      Primary objective: To evaluate compliance of LoFric Origo in a general intermittent&#xD;
      catheterization (IC) population with the use of LoFric Origo, by means of a subjective&#xD;
      assessment scale&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To evaluate the subject's perception associated with the use of the LoFric Origo, by&#xD;
           means of a subjective assessment scale&#xD;
&#xD;
        -  To evaluate the subject's discomfort associated with the use of the LoFric Origo, by&#xD;
           means of a subjective assessment scale&#xD;
&#xD;
        -  To observe and collect data on bladder regimen/IC frequency by assessments of&#xD;
           descriptive data of demography, catheter therapy, history and other patient reported&#xD;
           outcomes.&#xD;
&#xD;
      Study Design: Non-interventional study, multicentre, prospective study. Target Subject&#xD;
      Population: General intermittent catheterization, LoFric Origo male users.&#xD;
&#xD;
      Medical Device: LoFric Origo&#xD;
&#xD;
      Study Variable(s):&#xD;
&#xD;
        -  Primary variable: Use or No use of LoFric Origo after 8 weeks.&#xD;
&#xD;
        -  Secondary variable(s): patient reported questionnaire with regards to perception,&#xD;
           discomfort, diagnose, health status, catheter history and other patient reported&#xD;
           outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects still using LoFric Origo</measure>
    <time_frame>8 weeks</time_frame>
    <description>Outcome variable is to measure the proportion of subjects still using LoFric Origo after 8 weeks through subjective assessment scales.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perception of LoFric Origo</measure>
    <time_frame>8 weeks</time_frame>
    <description>Perception is a subjective sensation/impression which may be expressed in different ways. The concept of Perception, in this observational study, reflects each subject's own experience when using LoFric Origo and the subjects will evaluate the catheters with respect to a number of predetermined variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discomfort</measure>
    <time_frame>8 weeks</time_frame>
    <description>Evaluate subject's perceived discomfort associated with the use of the LoFric Origo, in terms of pain, burning sensation, bleeding and other discomfort.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">423</enrollment>
  <condition>Intermittent Catheterization</condition>
  <arm_group>
    <arm_group_label>LoFric Origo</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LoFric Origo</intervention_name>
    <arm_group_label>LoFric Origo</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients prescribed LoFric Origo for intermittent catheterization, attending any of the&#xD;
        involved clinics.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent.&#xD;
&#xD;
          2. Males, aged 18 years and over&#xD;
&#xD;
          3. Practice intermittent self-catheterization, at least one time daily&#xD;
&#xD;
          4. Subjects using LoFric Origo&#xD;
&#xD;
          5. Able to read and fill out a patient reported questionnaire as judge by the&#xD;
             investigator&#xD;
&#xD;
          6. The prescription of/decision to use the medical device is separated from the decision&#xD;
             to include the subject in the study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Simultaneous participation in any interfering clinical study&#xD;
&#xD;
          2. On-going, symptomatic urinary tract infection (UTI) at enrolment as judged by the&#xD;
             investigator&#xD;
&#xD;
          3. Involvement in the planning and/or conduct of the study (applies to both Wellspect&#xD;
             HealthCare staff and staff at the study site)&#xD;
&#xD;
          4. Previous enrolment in the present study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre de Traumatologie et de Readaptation</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liége</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Urologique de la Clinique Saint Augustin, Cabinet de Neuro-Urologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond Poincaré, Service de Neuro-Urologie, Urologie et Sexologie</name>
      <address>
        <city>Garche</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon, Service de Neuro-Urologie et Explorations Périnéales</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henry Gabrielle, Unité A1 - Service de Rééducation Périnéale et Sexologique</name>
      <address>
        <city>St Genis Laval</city>
        <zip>69230</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivas Zorggroep</name>
      <address>
        <city>Gorinchem</city>
        <state>Zuid-Holland</state>
        <zip>4204 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.M.C. St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akershus Universitetssykehus HF Urologisk poliklinikk</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnaas Sykehus HF Urodynamisk laboratorium</name>
      <address>
        <city>Nesoddtangen</city>
        <zip>1450</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF - Rikshospitalet Urologisk poliklinikk</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger Universitetssjukehus, Urologisk poliklinikk</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schweizer Paraplegiker-Zentrum, Neuro-Urologie</name>
      <address>
        <city>Nottwil</city>
        <zip>6207</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique romande de réadaptation</name>
      <address>
        <city>Sion</city>
        <zip>1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <state>Somerset</state>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire NHS Trust Walsgrave Hospital</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Exeter RD&amp;E Hospital</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital for Neurology and Neurosurgery Queens Square</name>
      <address>
        <city>London</city>
        <zip>WC1N 3GB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>February 20, 2013</study_first_submitted>
  <study_first_submitted_qc>February 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <last_update_submitted>May 7, 2015</last_update_submitted>
  <last_update_submitted_qc>May 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>July 18, 2019</submitted>
    <returned>August 27, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

